PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents growing 3.56% while TRAW's declined -10.80%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Both TRAW and the company show zero Short-Term Investments Growth.
3.51%
Below half of TRAW's -10.80%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half of TRAW's -9.73%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
11.32%
Below half TRAW's -9.16%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-18.41%
≥ 1.5x TRAW's -8.77%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half of TRAW's -9.72%. Michael Burry sees a potential red flag for stagnation or capital shortage.
65.90%
Above 1.5x TRAW's 7.24%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Less than half of TRAW's -63.06%. David Dodd sees fewer expansions in other current obligations.
114.06%
Less than half of TRAW's -12.15%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Less than half of TRAW's -42.10%. David Dodd sees far fewer liability expansions relative to competitor.
5.13%
Less than half of TRAW's -89.45%. David Dodd sees fewer share issuances vs. competitor.
-6.19%
Below half TRAW's 0.99%. Michael Burry suspects major net losses or high dividends vs. competitor.
-12.13%
50-75% of TRAW's -22.22%. Bruce Berkowitz notes relatively lower AOCI expansions.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-4.02%
Below half TRAW's 197.21%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
Below half TRAW's -9.72%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both TRAW and the company show zero Total Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of TRAW's 10.80%. David Dodd sees better deleveraging or stronger cash buildup than competitor.